Italia markets close in 49 minutes
FTSE MIB
35.379,84 -30,29 (-0,09%) Dow Jones
39.896,26 +26,88 (+0,07%) Nasdaq
16.718,79 +20,47 (+0,12%) Nikkei 225
38.787,38 -132,88 (-0,34%) Petrolio
79,45 +0,22 (+0,28%) Bitcoin EUR
61.057,12 +216,19 (+0,36%)
NBIX May 2024 100.000 call
OPR - OPR Prezzo differito. Valuta in USD.
Aggiungi a watchlist
In data: 02:02PM EDT. Mercato aperto.
| Chiusura precedente | 42,80 |
| Aperto | 42,80 |
| Denaro | 39,00 |
| Lettera | 43,30 |
| Prezzo d'esercizio | 100,00 |
| Scadenza | 2024-05-17 |
| Min-Max giorno | 36,45 - 42,80 |
| Contratto - Min-Max | N/D |
| Volume | |
| Open Interest | 1 |
GlobeNewswireSosei Heptares’ partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117570 in Healthy Adults
NBI-1117570 is an investigational, oral, muscarinic M1/M4 selective dual agonist discovered by Sosei Heptares that may have the potential to treat neurological and neuropsychiatric conditionsNBI-1117570 is the second compound to advance into clinical development from a portfolio of selective muscarinic receptor agonists licensed by Sosei Heptares to Neurocrine following NBI-1117568, an oral, selective muscarinic M4 receptor agonist, which is in Phase 2 clinical trials as an investigational treat
© 2024 Yahoo. Tutti i diritti riservati.